Background
Methods A probabilistic Markov model was developed to simulate both a bridge and a non-bridge cohort of AF patients periprocedurally (5 days before and 30 days after the procedure). Qualityadjusted life expectancy after the procedure, was the main outcome considered. The base case considered women 75-80 years old.
Strokes were modelled using CHA 2 DS 2 -VASc scores, incorporating the stroke preventive effects of warfarin and the LMWH using the INR trajectories. Longterm disabilities were taken into account using utility values. An increased postoperative stroke risk was applied, as compared to the population risks, using data published by Kaatz et al.
Bleedings were simulated using the rates as reported in the BRIDGE trial, as an average for many procedures. Two groups were included: low-risk (HAS-BLED 0-2) and high-risk patients (HAS-BLED ≥ 3). For high-risk patients, an additional bleeding risk was applied, as described in literature by Omran et al.
Results
The base case analysis shows that bridging anticoagulation increases the bleeding rate, but reduces the stroke rate. Bridging may be beneficial for the quality-adjusted life expectancy in patients with a CHA 2 DS 2 -VASc scores of 6 or higher and HAS-BLED scores of 0 to 2. Bridging is less likely to be beneficial if the life expectancy is shorter. For expected shorter periods to reach therapeutic INR, bridging therapy is less likely to be beneficial. 
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